medigraphic.com
ISSN 2992-8036 (Electronic)
ISSN 2306-4102 (Print)
Órgano Oficial del Colegio Mexicano de Ortopedia y Traumatología

2021, Number 4

<< Back Next >>

Acta Ortop Mex 2021; 35 (4)

Current status of chondrosarcoma in a reference center

Clara-Altamirano M, García-Ortega D, Núñez-González M, Caro-Sánchez C, Espejo-Sánchez G, Martínez-Said H, Cuéllar-Hübbe M

Language: Spanish
References: 17
Page: 300-304
PDF size: 168.53 Kb.


ABSTRACT

Introduction: Chondrosarcoma is the second most frequent primary malignant bone tumor, is characterized by the formation of a chondroid matrix, is more frequent in advanced ages and its prognosis is directly related to the histological subtype and tumor grade. The objective of this article is to present the demographic and treatment profile in a reference center. Material and methods: A retrospective, descriptive, observational, analytical cohort-type study was conducted in a reference center between January 1, 2005 and December 31, 2019, the demographic variables were analyzed and contrasted with the outcome variables that were overall survival and disease-free period. Results: 85 patients were included, the mean age of presentation was 43.3 years, the clinical stage at the time of presentation was mostly IIa and IIb covering 54.1%. 35 patients had metastases with clinical stage IV. The main site of metastasis was the lung in 32 patients (37.6%). Thirty-six patients (42.3%) had specific mortality. 35 patients (41.2%) died as a result of metastatic disease to lung or other organs, one patient died from direct extension of the tumor in the cervical spine. Conclusion: The important prognostic factors found in our series that influence global survival are: the presence of metastases and axial localization.


REFERENCES

  1. Chow WA. Chondrosarcoma: biology, genetics, and epigenetics. F1000Res. 2018; 7: F1000 Faculty Rev-1826.

  2. Gelderblom H, Hogendoorn PC, Dijkstra SD, van Rijswijk CS, Krol AD, Taminiau AH, et al. The clinical approach towards chondrosarcoma. Oncologist. 2008; 13: 320-9.

  3. Fromm J, Klein A, Baur-Melnyk A, Knosel T, Lindner L, Birkenmaier C, Dürr HR. Survival and prognostic factors in conventional G1 chondrosarcoma. World Journal of Surgical Oncology. 2019; 17(1): 155.

  4. Mankin HJ, Cantley KP, Schiller AL, Lippiello L. The biology of human chondrosarcoma. II. Variation in chemical composition among types and subtypes of benign and malignant cartilage tumors. J Bone Joint Surg Am. 1980; 62(2): 176-88.

  5. Zhu GG, Nafa K, Agaram N, Zehir A, Benayed R, Sadowska J, et al. Genomic profiling identifies association of IDH1/IDH2 mutation with longer relapse-free and metastasis-free survival in high-grade chondrosarcoma. Clinical Cancer Research. 2020; 26(2): 419-27.

  6. Meijer D, de Jong D, Pansuriya TC, van den Akker BE, Picci P, Szuhai K, et al. Genetic characterization of mesenchymal, clear cell, and dedifferentiated chondrosarcoma. Genes Chromosomes Cancer. 2012; 51(10): 899-909.

  7. Hirabayashi Y, Ishida T, Yoshida MA, Kojima T, Ehihara Y, Machinami R, et al. Translocation (9; 22)(g22; ql2) A recurrent chromosome abnormality in extraskeletal myxoid chondrosarcoma. Cancer Genetics and Cytogenetics. 1995; 81(1): 33-7.

  8. Riedel RF, Larrier N, Dodd L, Kirsch D, Martinez S, Brigman BE. The clinical management of chondrosarcoma. Curr Treat Options Oncol. 2009; 10(1-2): 94-106.

  9. Chen X, Yu LJ, Peng HM, Jiang C, Ye CH, Zhu SB, et al. Is intralesional resection suitable for central grade 1 chondrosarcoma: a systematic review and updated meta-analysis. Eur J Surg Oncol. 2017; 43(9): 1718-26.

  10. Amer KM, Munn M, Congiusta D, Abraham JA, Basu Mallick A. Survival and prognosis of chondrosarcoma subtypes: SEER database analysis. J Orthop Res. 2020; 38(2): 311-9.

  11. Saifuddin A, Sharif B, Oliveira I, Kalus S, Barnett J, Pressney I. The incidence of skip metastases on whole bone MRI in high-grade bone sarcomas. Skeletal Radiol. 2020; 1-10.

  12. Verdegaal SH, Bovée JV, Pansuriya TC, Grimer RJ, Ozger H, Jutte PC, et al. Incidence, predictive factors, and prognosis of chondrosarcoma in patients with Ollier disease and Maffucci syndrome: an international multicenter study of 161 patients. Oncologist. 2011; 16(12): 1771.

  13. Bergh P, Gunterberg B, Meis?Kindblom JM, Kindblom LG. Prognostic factors and outcome of pelvic, sacral, and spinal chondrosarcomas: a center?based study of 69 cases. Cancer. 2001; 91(7): 1201-12.

  14. Nota SP, Braun Y, Schwab JH, van Dijk CN, Bramer JA. The identification of prognostic factors and survival statistics of conventional central chondrosarcoma. Sarcoma. 2015, 2015: 623746.

  15. Tsuda Y, Evans S, Stevenson JD, Parry M, Fujiwara T, Laitinen M, Jeys L. Is the width of a surgical margin associated with the outcome of disease in patients with peripheral chondrosarcoma of the pelvis? A multicenter study. Clin Orthop Relat Res. 2019; 477(11): 2432-40.

  16. Badaruddin S, Mehtab P, Mubarak MD, Shakeel S, Sohail S. Chondrosarcoma pelvis: a review article. BAOJ Cancer Res Ther. 2019; 5: 062.

  17. Catanzano AA, Kerr DL, Lazarides AL, Dial BL, Lane WO, Blazer DG, et al. Revisiting the role of radiation therapy in chondrosarcoma: a national cancer database study. Sarcoma. 2019; 2019: 4878512.



EVIDENCE LEVEL

III




2020     |     www.medigraphic.com